無料プレビュー

Jazz Pharmaceuticals plc (JAZZ) · NASDAQ

プロフィール

Jazz Pharmaceuticals plc is a global biopharmaceutical company developing and commercializing life-changing medicines for patients with rare diseases, including epilepsies, cancers and sleep disorders. The company markets six lead products: Xywav for narcolepsy and idiopathic hypersomnia, Epidiolex for rare epilepsies, Ziihera for HER2-positive biliary tract cancer, Modeyso for diffuse midline glioma, Zepzelca for small cell lung cancer, and Rylaze for acute lymphoblastic leukemia. Jazz operates through direct commercial teams in the U.S., Europe, Australia and Canada, supported by a global ne

主要指標

株価: $222.45 (-3.78%)
時価総額: 140億ドル
PER（今期予想）: 8.9
PBR: 2.9
配当利回り: —
52週レンジ: $128.80 – $266.38
業種: Healthcare / Biotechnology
上場: NASDAQ
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-04 · 更新: 2026-10-09